Creating synthetic antibodies to block protein interactions
Multivalent protein-DNA nanostructures as synthetic blocking antibodies
This study is working on creating tiny synthetic antibodies that can stop certain proteins from interacting with each other, which is important for many biological processes, and it's aimed at helping researchers find better ways to target specific proteins in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arizona State University-Tempe Campus NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project ID | NIH-10877672 on NIH RePORTER |
What this research studies
This research focuses on developing innovative nanoscale synthetic antibodies, known as nano-synbodies, that can effectively block protein-protein interactions, which are crucial in many biological processes. By utilizing a combination of DNA nanostructures and peptide/protein ligands, the project aims to create tailored solutions that can bind to specific surfaces of target proteins, preventing their interactions. The approach involves advanced computational simulations to design and optimize these nano-synbodies before experimental testing, ensuring high specificity and effectiveness in blocking unwanted protein interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals affected by diseases that involve problematic protein-protein interactions, such as COVID-19.
Not a fit: Patients with conditions unrelated to protein interactions or those not affected by COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for diseases where protein interactions play a critical role, including COVID-19.
How similar studies have performed: While the approach of using synthetic antibodies is innovative, similar strategies in blocking protein interactions have shown promise in other research, indicating potential for success.
Where this research is happening
Tempe, United States
- Arizona State University-Tempe Campus — Tempe, United States (Active)
Researchers
- Principal investigator: Stephanopoulos, Nicholas — Arizona State University-Tempe Campus
- Study coordinator: Stephanopoulos, Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.